Trial NCT04533399; PACTR202009726132275
Publication Madhi S, Lancet HIV, 2022
Primary outcome on the report: To evaluate the reactogenicity and safety of NVX-CoV2373 during the 14 days after the second injection (day 35) in both HIV-negative individuals and people living with HIV-1;

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.